MC5R — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL368269	0.53	16/20
SCHEMBL279121	0.50	10/20
SCHEMBL332838	0.49	10/20
Cilengitide (SCHEMBL451423)	0.52	9/20
SCHEMBL70497	0.62	7/20
SCHEMBL71981	0.62	7/20
SCHEMBL71984	0.62	7/20
SCHEMBL91103	0.62	7/20
SCHEMBL63838	0.75	6/20
SCHEMBL70501	0.75	6/20
SCHEMBL91100	0.75	6/20
SCHEMBL130385	0.57	6/20
SCHEMBL136034	0.57	6/20
Argadin (SCHEMBL141316)	0.39	6/20
Hydrochloric Acid (SCHEMBL302608)	0.49	5/20
SCHEMBL415523	0.43	5/20
SCHEMBL91137	0.62	4/20
Eptifibatide (SCHEMBL43237)	0.59	4/20
SCHEMBL342657	0.53	4/20
SCHEMBL675779	0.45	4/20

Clinical trials — most relevant to MC5R by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Efficacy and Safety of H.P. Acthar Gel for the Treatment of Refractory Cutaneous Manifestations of Dermatomyositis	PHASE4	COMPLETED
Weight Loss Study: Genetics and Response to Naltrexone/Bupropion	PHASE4	RECRUITING
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes	PHASE3	RECRUITING
Long Term Extension Trial of Setmelanotide	PHASE2/PHASE3	COMPLETED
Effects of Acthar on Recovery From Cognitive Relapses in MS	PHASE3	COMPLETED
ACTH as A Re-emerging theRapy for Uveitis (The ACTHAR Study)	PHASE2	COMPLETED
Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Diffuse Cutaneous Systemic Sclerosis	PHASE2	COMPLETED
Safety and Efficacy of Different Combinations of Zonisamide-CR Plus Bupropion-SR to Treat Uncomplicated Obesity	PHASE2	COMPLETED
This Study Will Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of MET097 in Adult Participants With Overweight or Obesity	PHASE1/PHASE2	COMPLETED
A Clinical Study to Evaluate the Potential Role of ACTH Gel in Patients With Scleritis	PHASE2	UNKNOWN
RM-493 Treatment Trial in Proopiomelanocortin (POMC) Deficient Patients	PHASE2	UNKNOWN
Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs Placebo	PHASE2	ACTIVE_NOT_RECRUITING
Studying the Influence of LEAP2 on Integrated Endocrine Control of Eating During Semaglutide Treatment	PHASE1/PHASE2	RECRUITING
Setmelanotide to Treat Obesity in a Patient With Pseudohypoparathyroidism Type 1a (PHP1a)	PHASE2	NOT_YET_RECRUITING
Effects of RM-493 on Energy Expenditure in Obese Individuals	PHASE1	COMPLETED
Effect of Adrenocorticotropic Hormone on Vascular Endothelial Growth Factor Release in Children Study	EARLY_PHASE1	COMPLETED
Protocol for Alpha MSH Infusion Study in Patients With Type 2 Diabetes	nan	UNKNOWN
Retrospective Evaluation of Melanocortin Receptor 4 Polymorphisms in Patients With GBM Treated With Radiochemotherapy	nan	COMPLETED
Vanderbilt Childhood Obesity Registry	nan	COMPLETED
Melanocortin 4 Receptor Mutations and Obesity-associated Diseases	nan	COMPLETED
Rare Obesity Cohorts With Food Behavioral Disorders : Better Diagnosis for Better Treatment	nan	RECRUITING
Examination of Brain Serotonin Receptors in Patients With Mood Disorders	nan	COMPLETED
Brain-Derived Neurotrophic Factor in Obesity and Brain Function	nan	COMPLETED
Sequencing of 14 Genes From Leptin Melanocortin Pathway in Severe Obesity in Childhood.	nan	UNKNOWN
Eating Behavior in Children	nan	COMPLETED
The TEMPO (Tracing the Effect of the MC4 Pathway in Obesity) Registry	nan	COMPLETED
Assessing Obesity Related Risk Factors in Adult Population: A Genetic and Behavioral Study	nan	ENROLLING_BY_INVITATION
Effect of Vestibular Stimulation on Fat Consumption and Energy Expenditure as Assessed Using Indirect Calorimetry	nan	COMPLETED
A Personalized Program of Physical Activity and Diet for Hypothalamic Obesity	nan	COMPLETED
Study of the Hypothalmic-Pituitary-Adrenal (HPA) Axis and Its Role in Major Depression	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a MC5R binder may also engage these)

Protein	Name	Similarity
P56451	—	1.000	P56451 →
Q9TT23	—	1.000	Q9TT23 →
P41983	—	1.000	P41983 →
O97504	—	1.000	O97504 →
P33033	—	1.000	P33033 →
P32244	—	1.000	P32244 →
P70596	—	1.000	P70596 →
MC4R	Melanocortin receptor 4	1.000	landscape →
Q8HXX3	—	1.000	Q8HXX3 →
P34974	—	1.000	P34974 →
P35345	—	1.000	P35345 →
P56450	—	1.000	P56450 →
Q9MZV8	—	0.999	Q9MZV8 →
MC3R	Melanocortin receptor 3	0.999	landscape →
B0V1P1	—	0.999	B0V1P1 →
Q9TU77	—	0.999	Q9TU77 →
P41149	—	0.998	P41149 →
MC2R	Adrenocorticotropic hormone receptor	0.996	landscape →
Q9GLJ8	—	0.996	Q9GLJ8 →
Q0Z8I9	—	0.996	Q0Z8I9 →
Q9Z1S9	—	0.995	Q9Z1S9 →
P70115	—	0.994	P70115 →
Q8HYN8	—	0.993	Q8HYN8 →
Q01727	—	0.990	Q01727 →
Q80SS9	—	0.990	Q80SS9 →
Q64326	—	0.989	Q64326 →
P55167	—	0.989	P55167 →
Q80SZ5	—	0.988	Q80SZ5 →
Q864I2	—	0.987	Q864I2 →
Q6A155	—	0.986	Q6A155 →